GlassScriptPhysician profile
Charles N Le
NPI 1821243759
$13,894.75
in general payments reported to CMS, 2019-2025
48 companies · $3,594 in 2025
The $3,594 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $796 · 2021: $2,177 · 2022: $2,253 · 2023: $1,946 · 2024: $2,113 · 2025: $3,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,548 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,547.53 |
| Education | $105.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,048.84 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Horizon Therapeutics Plc | $1,108.46 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $1,104.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,092.19 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $691.71 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $669.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $590.69 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $588.46 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $574.61 | 2019-2022 | |
| Ardelyx, INC. | $483.82 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $477.71 | 2019-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $405.40 | 2019-2024 | Rayaldee |
| Gastroklenz, INC. Dba Cloudcath | $400.00 | 2022 | |
| Vifor Pharma, INC. | $359.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $354.48 | 2020-2024 | Benlysta |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.